{"id":63501,"date":"2025-01-10T12:04:58","date_gmt":"2025-01-10T12:04:58","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2025\/01\/10\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/"},"modified":"2025-01-10T12:04:58","modified_gmt":"2025-01-10T12:04:58","slug":"belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/","title":{"rendered":"Belharra Therapeutics Announces Appointment of Sean Buchanan, Ph.D., as Chief Scientific Officer and Retirement of Gary O\u2019Neill, Ph.D."},"content":{"rendered":"<div>\n<ul>\n<li style=\"text-align:left;\">Dr. Buchanan will helm Belharra\u2019s research organization as the company progresses its lead immunology and oncology programs, advances activities with its pharma collaborators, and enriches its Searchlight&#x2122; chemoproteomics platform<\/li>\n<\/ul>\n<p align=\"left\">SAN MATEO, Calif. and SAN DIEGO, Jan.  10, 2025  (GLOBE NEWSWIRE) &#8212; Belharra Therapeutics, a next-generation chemoproteomics company transforming small molecule drug discovery by illuminating binding pockets on elusive, high-value drug targets across the proteome, today announced the appointment of Sean Buchanan, Ph.D., as Chief Scientific Officer (CSO). Dr. Buchanan, who previously served as Senior Vice President, Head of Biology at Belharra, assumed leadership of the company\u2019s research organization upon the concurrent, planned retirement of Gary O\u2019Neill, Ph.D., the company\u2019s founding CSO. Dr. O\u2019Neill will continue to serve as a senior advisor to Belharra.<\/p>\n<p>\u201cWe are thrilled to announce Sean Buchanan\u2019s appointment as Belharra\u2019s new CSO. His ascension to this role is a natural evolution based on the significant impact he has had scientifically, strategically, operationally, and culturally at Belharra,\u201d said Jeff Jonker, Chief Executive Officer at Belharra. \u201cI look forward to Sean\u2019s skillful leadership and close collaboration as we continue to advance our lead internal oncology and immunology programs, progress the exciting activities underway with our pharma partners, and enrich our Searchlight&#x2122; chemoproteomics platform.\u201d<\/p>\n<p>Mr. Jonker continued, \u201cI am profoundly grateful to Gary O\u2019Neill for his immeasurable contributions to Belharra. Gary established our research organization and solidified it with his wealth of experience as a seasoned biotech executive and his expertise as a talented people leader. By balancing long-term vision and near-term pragmatism, Gary skillfully laid the groundwork that will enable us to grow and thrive as we advance our mission on behalf of patients. We look forward to Gary\u2019s continued impact as a senior advisor, and we wish him all the best in his well-deserved and no doubt hugely productive retirement.\u201d<\/p>\n<p>Dr. Buchanan commented, \u201cI\u2019m very excited to embark on this new journey as CSO, working with my talented colleagues at Belharra, as we build on the firm scientific foundation Gary established as my predecessor. 2025 will be a pivotal year for Belharra as we see the novel insights that we\u2019ve uncovered through our uniquely unbiased chemoproteomics screening capabilities translate to investigational medicines with groundbreaking potential to help patients in need.\u201d<\/p>\n<p>Prior to joining Belharra, Dr. Buchanan served as Executive Director of Cancer Therapeutics at Genomics Institute of the Novartis Research Foundation (GNF), where he was responsible for the Novartis Institutes for BioMedical Research (NIBR) San Diego Oncology Drug Discovery portfolio. Prior to Novartis, Dr. Buchanan was at Eli Lilly for over a decade, serving in various roles and contributing to multiple cancer medicines and drug candidates. He began his industry career in 1999 at SGX Pharmaceuticals (acquired by Eli Lilly in 2008), where he led the biology team.<\/p>\n<p>Dr. Buchanan received his Ph.D. and Master\u2019s degrees in Biochemistry at Cambridge University in the UK and did his post-doctoral research in Molecular Genetics at University of California San Diego.<\/p>\n<p><strong>About Belharra Therapeutics<\/strong><\/p>\n<p>Belharra Therapeutics, Inc. is a next-generation chemoproteomics company developing a pipeline of first-in-class and best-in-class small molecule therapeutics for well validated targets in oncology and immunology. We aim to transform non-covalent small molecule drug discovery by illuminating binding pockets on elusive, high-value targets across the proteome using our proprietary Searchlight&#x2122; screening platform.<\/p>\n<p>Complementing our internal discovery efforts, we partner with industry-leading companies, lending the power of our platform to find new starting points for groundbreaking medicines targeting partner-identified proteins across all disease areas while growing the platform\u2019s datasets.<\/p>\n<p>Belharra\u2019s primary lab and offices are in San Diego, California, with an additional presence in the San Francisco Bay Area.\u00a0To learn more, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JL7BGHT9pW_BJzDOgk7jpX932g2dQkrQhepm7fMh5VGy7HETmIbfrMNFzDx8XvIq0-wr7VcrGrgvdjOcuOohiW6Q_HVgyi6UEGYwmDF7NY0=\" rel=\"nofollow\" target=\"_blank\" title=\"www.belharratx.com\">www.belharratx.com<\/a>.<\/p>\n<p>Contacts: <br \/>Liz Melone<br \/>(617) 256-6652<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XJmt7-cAh1evYy9JxmEtqc-l4SZYv5TPF8q0cnRkh-uM_Qf7uKVcqlFDSPjNFD5IYSN5crABQZzlcWlJ93Qs_d2Z2x_e7LNwawREzI5pZjk=\" rel=\"nofollow\" target=\"_blank\" title=\"liz@melonecomm.com\">liz@melonecomm.com<\/a><\/p>\n<p>Jessi Rennekamp<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xsWwjskvt0zMqkg-DfJsPu9eF0j220aU-ebWH8NG1HEpQMUwzRGbMLCWwIgCl3rEWk4TqV48L3qUaPwue-B7LU8wbUdxsPEaCxcSt5F5vlc=\" rel=\"nofollow\" target=\"_blank\" title=\"jessi@astriorcomms.com\">jessi@astriorcomms.com<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2E1MDAwMWEtN2I1Zi00MTUwLWE1M2ItMTNmOTcyNmIyY2Y0LTEyNTg1Nzc=\/tiny\/Belharra-Therapeutics-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Buchanan will helm Belharra\u2019s research organization as the company progresses its lead immunology and oncology programs, advances activities with its pharma collaborators, and enriches its Searchlight&#x2122; chemoproteomics platform SAN MATEO, Calif. and SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) &#8212; Belharra Therapeutics, a next-generation chemoproteomics company transforming small molecule drug discovery by illuminating binding [&#8230;]\n","protected":false},"author":1,"featured_media":63502,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-63501","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Belharra Therapeutics Announces Appointment of Sean Buchanan, Ph.D., as Chief Scientific Officer and Retirement of Gary O\u2019Neill, Ph.D. - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Belharra Therapeutics Announces Appointment of Sean Buchanan, Ph.D., as Chief Scientific Officer and Retirement of Gary O\u2019Neill, Ph.D.\" \/>\n<meta property=\"og:description\" content=\"Dr. Buchanan will helm Belharra\u2019s research organization as the company progresses its lead immunology and oncology programs, advances activities wit\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-10T12:04:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/01\/Belharra-Therapeutics-Inc-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Belharra Therapeutics Announces Appointment of Sean Buchanan, Ph.D., as Chief Scientific Officer and Retirement of Gary O\u2019Neill, Ph.D.\",\"datePublished\":\"2025-01-10T12:04:58+00:00\",\"dateModified\":\"2025-01-10T12:04:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/\"},\"wordCount\":658,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/\",\"name\":\"Belharra Therapeutics Announces Appointment of Sean Buchanan, Ph.D., as Chief Scientific Officer and Retirement of Gary O\u2019Neill, Ph.D. - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2025-01-10T12:04:58+00:00\",\"dateModified\":\"2025-01-10T12:04:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Belharra Therapeutics Announces Appointment of Sean Buchanan, Ph.D., as Chief Scientific Officer and Retirement of Gary O\u2019Neill, Ph.D.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Belharra Therapeutics Announces Appointment of Sean Buchanan, Ph.D., as Chief Scientific Officer and Retirement of Gary O\u2019Neill, Ph.D. - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/","og_locale":"en_US","og_type":"article","og_title":"Belharra Therapeutics Announces Appointment of Sean Buchanan, Ph.D., as Chief Scientific Officer and Retirement of Gary O\u2019Neill, Ph.D.","og_description":"Dr. Buchanan will helm Belharra\u2019s research organization as the company progresses its lead immunology and oncology programs, advances activities wit","og_url":"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2025-01-10T12:04:58+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/01\/Belharra-Therapeutics-Inc-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Belharra Therapeutics Announces Appointment of Sean Buchanan, Ph.D., as Chief Scientific Officer and Retirement of Gary O\u2019Neill, Ph.D.","datePublished":"2025-01-10T12:04:58+00:00","dateModified":"2025-01-10T12:04:58+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/"},"wordCount":658,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/","url":"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/","name":"Belharra Therapeutics Announces Appointment of Sean Buchanan, Ph.D., as Chief Scientific Officer and Retirement of Gary O\u2019Neill, Ph.D. - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2025-01-10T12:04:58+00:00","dateModified":"2025-01-10T12:04:58+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/belharra-therapeutics-announces-appointment-of-sean-buchanan-ph-d-as-chief-scientific-officer-and-retirement-of-gary-oneill-ph-d\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Belharra Therapeutics Announces Appointment of Sean Buchanan, Ph.D., as Chief Scientific Officer and Retirement of Gary O\u2019Neill, Ph.D."}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/63501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=63501"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/63501\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/63502"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=63501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=63501"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=63501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}